Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Natera Inc (NQ: NTRA ) 123.98 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Natera Inc < Previous 1 2 3 4 5 6 7 8 9 ... 11 12 Next > Planet Fitness To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday May 14, 2024 Via Benzinga Key Takeaways From Natera Analyst Ratings May 13, 2024 Via Benzinga Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session May 10, 2024 Via Benzinga How Is The Market Feeling About Natera? May 09, 2024 Via Benzinga Looking Into Natera's Recent Short Interest April 23, 2024 Via Benzinga Genpact Posts Upbeat Earnings, Joins Groupon, Natera, Funko, CarGurus And Other Big Stocks Moving Higher On Friday May 10, 2024 Via Benzinga Why Natera Is 'A Stock To Focus On' Following Its Mighty Beat-And-Raise May 10, 2024 The company put up a "robust" beat and raise following an increase in test volume and sales prices in women's health and cancer detection. Via Investor's Business Daily Why Natera Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket May 10, 2024 Via Benzinga Cracking The Code: Understanding Analyst Reviews For Natera April 05, 2024 Via Benzinga Looking Into Natera's Recent Short Interest April 05, 2024 Via Benzinga Natera Inc. (NASDAQ: NTRA) Records 52-Week High Friday Morning April 05, 2024 Via Investor Brand Network 12 Health Care Stocks Moving In Friday's Pre-Market Session May 10, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday May 10, 2024 The biggest pre-market stock movers are ready to go as we check out all of the hottest news happening on Friday morning! Via InvestorPlace US Stocks Set To End Week Strong With S&P 500 Eyeing Break Above Late-March Peak: Analyst Says He's Still A Buy In May Amid This Positive Signal May 10, 2024 U.S. stocks are on track to finish the week on a high, with the index futures pointing to a higher opening on Friday. Via Benzinga Topics Stocks Exposures US Equities Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life May 10, 2024 Genomics is the future of medicine, creating big opportunity for some of the top genomics stock picks to buy today. Via InvestorPlace NTRA Stock Earnings: Natera Beats EPS, Beats Revenue for Q1 2024 May 09, 2024 NTRA stock results show that Natera beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace 12 Health Care Stocks Moving In Thursday's After-Market Session May 09, 2024 Via Benzinga Natera Reports First Quarter 2024 Financial Results May 09, 2024 From Natera, Inc. Via Business Wire New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer May 03, 2024 From Natera, Inc. Via Business Wire Natera to Report its First Quarter 2024 Results on May 9 May 01, 2024 From Natera, Inc. Via Business Wire Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage May 01, 2024 From Natera, Inc. Via Business Wire Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications April 22, 2024 From Natera, Inc. Via Business Wire Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation April 11, 2024 From Natera, Inc. Via Business Wire Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients April 08, 2024 From Natera, Inc. Via Business Wire Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer April 05, 2024 From Natera, Inc. Via Business Wire Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer April 01, 2024 From Natera, Inc. Via Business Wire Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer March 18, 2024 From Natera, Inc. Via Business Wire New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease March 14, 2024 From Natera, Inc. Via Business Wire Disney, Natera, Chubb And A Major Tech Stock On CNBC's 'Final Trades' March 12, 2024 On CNBC’s "Halftime Report Final Trades," Amy Raskin of Chevy Chase Trust said Natera, Inc. Via Benzinga Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers March 12, 2024 From Natera, Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 ... 11 12 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.